Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: Coherent Market Insights | PRODUCT CODE: 1740101

Cover Image

PUBLISHER: Coherent Market Insights | PRODUCT CODE: 1740101

Neuropathic Ocular Pain Market, By Drug Class, By Distribution Channel, And by Region

PUBLISHED:
PAGES: 170 Pages
DELIVERY TIME: 2-3 business days
SELECT AN OPTION
PDF (Single User License)
USD 4500
PDF (Multi User License)
USD 7000
PDF (Enterprise User License)
USD 10000

Add to Cart

Neuropathic Ocular Pain Market is estimated to be valued at USD 209.6 Mn in 2025 and is expected to reach USD 260.1 Mn by 2032, growing at a compound annual growth rate (CAGR) of 3.13% from 2025 to 2032.

Report Coverage Report Details
Base Year: 2024 Market Size in 2025: USD 209.6 Mn
Historical Data for: 2020 To 2024 Forecast Period: 2025 To 2032
Forecast Period 2025 to 2032 CAGR: 3.13% 2032 Value Projection: USD 260.1 Mn

Neuropathic pain is a pain condition that's usually chronic. It's usually caused by chronic, progressive nerve disease, and it can also occur as the result of injury or infection. Ocular neuropathic pain, also referred to as corneal neuropathic pain, is a condition where corneal pain is seen in response to normally non-painful stimuli. This results from repeated direct damage to corneal nerves. This damaged nerve sends pain signals to central nervous system (CNS) even in the absence of painful stimulus, thus, called "pain without stain" or "phantom cornea'. This condition is the ocular analog of systemic neuropathic pain, a complex regional pain syndrome, or reflex sympathetic dystrophy (RSD). Ocular or corneal neuropathic pain, corneal neuropathy, corneal neuralgia, kertaoneuralgia, and corneal allodynia are all terms that are used to describe the same disease entity.

Market Dynamics

An increase in government and non-government organizations' initiatives to improve access to affordable vision care and an increase in awareness among people regarding eye-related disease are expected to drive the market growth. Moreover, an increase in product launches by key market players is expected to drive the market growth over the forecast period. For instance, in November 2021, I-MED Pharma inc., a privately held Canada based eye care company, announced that it had launched an entire portfolio of dry eye products in the U.S. The products such as I-DROP, I-DEFENCE, and others, are intended to provide long-lasting relief from eye dryness, which is caused due to neuropathic ocular pain.

Key features of the study:

  • This report provides an in-depth analysis of the global neuropathic ocular pain market, and provides market size (US$ Million) and compound annual growth rate (CAGR%) for the forecast period 2025-2032, considering 2024 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global neuropathic ocular pain market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
  • Key companies covered as a part of this study include OKYO Pharma, Limited, Ocular Therapeutix, Inc., IACTA Pharmaceuticals, Inc., Sun Pharmaceutical Industries Ltd., Novartis AG, SALVAT, AbbVie Inc., Bausch & Lomb Incorporated, Kala Pharmaceuticals, Spectra Vision Care, Alcon Laboratories, AERIE PHARMACEUTICALS, INC., Optocred Pharmaceuticals and BRIM Biotechnology, Inc.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • The global neuropathic ocular pain market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global neuropathic ocular pain market

Detailed Segmentation:

  • Global Neuropathic Ocular Pain Market, By Drug Class:
    • Steroids
    • Non-Steroidal Anti-Inflammatory Drugs
    • Antidepressants
    • Anticonvulsants
    • Opioids
    • Others (Vitamin B supplements, Botulinum toxin A, and others)
  • Global Neuropathic Ocular Pain Market, By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Global Neuropathic Ocular Pain Market, By Region:
    • North America
    • Europe
    • Asia Pacific
    • Latin America
    • Middle East & Africa
  • Company Profiles
    • OKYO Pharma Limited
    • Ocular Therapeutix, Inc.
    • IACTA Pharmaceuticals, Inc.
    • Sun Pharmaceutical Industries Ltd.
    • Novartis AG
    • SALVAT
    • AbbVie Inc.
    • Bausch & Lomb Incorporated
    • Kala Pharmaceuticals
    • Spectra Vision Care.
    • Alcon Laboratories
    • AERIE PHARMACEUTICALS, INC.
    • Optocred Pharmaceuticals
    • BRIM Biotechnology, Inc.
Product Code: CMI5600

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snapshot, By Drug Class
    • Market Snapshot, By Distribution Channel
    • Market Snapshot, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Drivers
    • Restraints
    • Market Opportunities
  • Impact Analysis
  • Recent Product Launches
  • Epidemiology
  • Merger, Acquisition, and Collaborations
  • Regulatory Scenario
  • Key Developments
  • PEST Analysis
  • Pipeline Analysis

4. Global Neuropathic Ocular Pain Market - Impact of Coronavirus (Covid-19) Pandemic

  • Economic Impact
  • COVID-19 Epidemiology
  • Impact on Supply and Demand

5. Global Neuropathic Ocular Pain Market, By Drug Class, 2020 - 2032, (US$ Million)

  • Overview
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021 - 2032
    • Segment Trends
  • Steroids
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Million)
  • Non-Steroidal Anti-Inflammatory Drugs
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Million)
  • Antidepressants
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Million)
  • Anticonvulsants
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Million)
  • Opioids
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Million)
  • Others (Vitamin B supplements, Botulinum toxin A, and others)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Million)

6. Global Neuropathic Ocular Pain Market, By Distribution Channel, 2020 - 2032, (US$ Million)

  • Overview
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021 - 2032
    • Segment Trends
  • Hospital Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Million)
  • Retail Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Million)
  • Online Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Million)

7. Global Neuropathic Ocular Pain Market, By Region, 2020 - 2032, (US$ Million)

  • Overview
    • Market Share Analysis, By Region, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, For Regions, 2021-2032
    • Regional Trends
  • North America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2032, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (US$ Million)
      • U.S.
      • Canada
  • Latin America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2032, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (US$ Million)
      • Brazil
      • Mexico
      • Argentina
      • Rest of Latin America
  • Europe
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2032, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (US$ Million)
      • U.K.
      • Germany
      • Italy
      • France
      • Spain
      • Russia
      • Rest of Europe
  • Asia Pacific
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2032, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (US$ Million)
      • China
      • India
      • Japan
      • ASEAN
      • Australia
      • South Korea
      • Rest of Asia Pacific
  • Middle East
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2032, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (US$ Million)
      • GCC
      • Israel
      • Rest of Middle East
  • Africa
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2032, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2020 - 2032, (US$ Million)
      • North Africa
      • Central Africa
      • South Africa

8. Competitive Landscape

  • OKYO Pharma, Limited
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Ocular Therapeutix, Inc.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • IACTA Pharmaceuticals, Inc.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Sun Pharmaceutical Industries Ltd.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Novartis AG
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • SALVAT
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • AbbVie Inc.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Bausch & Lomb Incorporated
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Kala Pharmaceuticals
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Spectra Vision Care
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Alcon Laboratories
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • AERIE PHARMACEUTICALS, INC.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Optocred Pharmaceuticals
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • BRIM Biotechnology, Inc.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies

9. Section

  • Research Methodology
  • About Us
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!